Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 24
- Registration Number
- NCT06745882
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 12
- Registration Number
- NCT06732258
First-line Treatment with RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 110
- Registration Number
- NCT06730373
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Shengli Oilfield Central Hospital, Dongying, Shandong, China
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
- Conditions
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06725498
- Locations
- 🇨🇳
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 159
- Registration Number
- NCT06724042
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 112
- Registration Number
- NCT06718205
- Locations
- 🇨🇳
Feng Wang, Zhengzhou, Henan, China
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dai, Guanghai
- Target Recruit Count
- 35
- Registration Number
- NCT06708858
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 430
- Registration Number
- NCT06704620
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 460
- Registration Number
- NCT06706401
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
The Minimalist Trial-2
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 153
- Registration Number
- NCT06702033
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.